Pfizer pumps $120M investment into Kalamazoo plant for Paxlovid production
As Pfizer is continuing to double down on its Paxlovid efforts, more room at its facility in Michigan will now be required.
The pharma will be committing $120 million on its own to its 1,300-acre manufacturing facility in Kalamazoo, MI to enable US-based production in support of its Covid-19 oral antiviral.
According to the pharmaceutical giant, the investment will expand the production of the API and RSMs used in the manufacture of nirmatrelvir, a key component in Paxlovid. The company expects the expansion will create more than 250 additional jobs at the Kalamazoo site.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.